Schizophrenia Clinical Trials in San Antonio

Showing 101-116 of 116 trials

The Consta Club: A Demonstration Project for Setting up a Consta Club in a Community Mental Health Center

NCT00845572

This study will establish a bi-weekly Consta Club. Participants will begin taking Risperdal Consta after being recommended by their treating physician. As a part of the Consta Club attendees will receive their injection of Risperdal Consta and be educated about important mental health issues. Interviews with study participants will be completed every three months to determine the effectiveness of the change to Risperdal Consta and the bi-weekly group. The overall hypothesis is that the individuals in Consta Club will have a decrease in walk-in visits, emergency procedures and hospitalizations. It is also believed that individuals in Consta Club will have fewer symptoms and better levels of functioning.

SchizophreniaSchizoaffective

The University of Texas Health Science Center at San Antonio30 participantsStarted Jan 2007

San Antonio, Texas, United States

TERMINATEDPhase 3< 1 mile

Compare the Effects of Bifeprunox and Quetiapine on Weight Changes in Stable Schizophrenic Patients

NCT00396214

The primary objective of the study is to evaluate changes in weight short and long term with bifeprunox and quetiapine. Study participation for the subject is 57 weeks.

Schizophrenia

Solvay Pharmaceuticals83 participantsStarted Apr 2007

Anaheim, California, United States • Anaheim, California, United States • Cerritos, California, United States +148 more locations

The Consta Club: A Demonstration Project for Setting up a Consta Club in a Community Mental Health Center

Compare the Effects of Bifeprunox and Quetiapine on Weight Changes in Stable Schizophrenic Patients

Schizophrenia Trials in Other Cities

Switch Study of Existing Atypical Antipsychotics to Bifeprunox

A Combination of Two Currently Approved Drugs to Enhance the Treatment of Schizophrenia

28-30 Month Study Comparing Paliperidone Palmitate With Oral Risperidone for Treating Adults Diagnosed With Schizophrenia Within the Past 5 Years

Study to Evaluate the Efficacy and Safety of Armodafinil as Adjunctive Therapy in Adults With Schizophrenia

Efficacy Study of Early Onset of Antipsychotic Drug Action in Schizophrenia

Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol and Risperidone

Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder

Olanzapine Versus Placebo in the Treatment of Adolescents With Schizophrenia

Effects of Cariprazine on Cardiac Repolarization in Patients With Schizophrenia

The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder

To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia

A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children

Olanzapine Given in Combination With Zonisamide SR to Prevent Weight Gain in Schizophrenic Subjects

Large Simple Trial (LST) Of Cardiovascular Safety Of Ziprasidone And Olanzapine- (Zodiac)

Other Conditions in San Antonio